Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Nivolumab plus ipilimumab versus nivolumab in individuals with treatment-naive programmed death-ligand 1 positive metastatic soft tissue sarcomas: a multicentre retrospective study

Fig. 2

Kaplan–Meier curves for overall survival. The median overall survival was 12.2 months (95% CI, 6.1–13.7) and 9.2 months (95% CI, 4.2–11.5) for the NPI and NIV groups, respectively (HR 0.49, 95% CI, 0.33–0.73; p=0.0002). Significant differences were detected in the overall survival between groups. *The hazard ratio was calculated using a Cox proportional hazards model, with age, the sarcoma types, the number of metastatic sites, and the ECOG performance status as covariates and NPI or NIV therapy as the time-dependent factor

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us